Premium
Bullous pemphigoid: What's ahead?
Author(s) -
Furue Masutaka,
Kadono Takafumi
Publication year - 2016
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.13207
Subject(s) - bullous pemphigoid , hemidesmosome , immunology , autoantibody , antibody , medicine , pathology , pemphigoid , disease , dermatology , basement membrane
Bullous pemphigoid ( BP ) is an autoimmune subepidermal blistering skin disease mainly affecting older individuals. Pathogenic autoantibodies preferentially target the non‐collagenous 16A domain of collagen XVII (also called BP antigen 2, BPAG 2) present in hemidesmosomes. The pathogenic anti‐ BPAG 2 antibodies cause the dermal–epidermal separation in neonatal and adult mice as well as in cryosections of human skin. These experimental BP models stress a pivotal role for neutrophils and the Fcγ receptor of immunoglobulins. Mice that have been genetically manipulated in the pathogenic domain of BPAG 2 spontaneously develop subepidermal blistering with pruritus and eosinophilic infiltration. BPAG 2 is physiologically and aberrantly expressed in neuronal tissue and internal malignancies, and the associations of BP with Parkinson's disease, stroke and internal malignancies invites new investigations into the immunological dysregulation behind the comorbidity.